Targeted therapy using nanocomposite delivery systems in cancer treatment: highlighting miR34a regulation for clinical applications

Basit Öğe Kaydı
dc.authoridCalina, Daniela/0000-0002-1523-9116
dc.authoridSharifi-Rad, Javad/0000-0002-7301-8151
dc.contributor.authorIqbal, Muhammad Javed
dc.contributor.authorJaved, Zeeshan
dc.contributor.authorSadia, Haleema
dc.contributor.authorMehmood, Sajid
dc.contributor.authorAkbar, Ali
dc.contributor.authorZahid, Benish
dc.contributor.authorNadeem, Tariq
dc.date.accessioned2024-10-26T18:11:34Z
dc.date.available2024-10-26T18:11:34Z
dc.date.issued2023
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractThe clinical application of microRNAs in modern therapeutics holds great promise to uncover molecular limitations and conquer the unbeatable castle of cancer metastasis. miRNAs play a decisive role that regulating gene expression at the post-transcription level while controlling both the stability and translation capacity of mRNAs. Specifically, miR34a is a master regulator of the tumor suppressor gene, cancer progression, stemness, and drug resistance at the cell level in p53-dependent and independent signaling. With changing, trends in nanotechnology, in particular with the revolution in the field of nanomedicine, nano drug delivery systems have emerged as a prominent strategy in clinical practices coupled with miR34a delivery. Recently, it has been observed that forced miR34a expression in human cancer cell lines and model organisms limits cell proliferation and metastasis by targeting several signaling cascades, with various studies endorsing that miR34a deregulation in cancer cells modulates apoptosis and thus requires targeted nano-delivery systems for cancer treatment. In this sense, the present review aims to provide an overview of the clinical applications of miR34a regulation in targeted therapy of cancer.
dc.identifier.doi10.1186/s12935-023-02929-3
dc.identifier.issn1475-2867
dc.identifier.issue1
dc.identifier.pmid37149609
dc.identifier.scopus2-s2.0-85159959703
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1186/s12935-023-02929-3
dc.identifier.urihttps://hdl.handle.net/20.500.12418/30736
dc.identifier.volume23
dc.identifier.wosWOS:000982685800001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBmc
dc.relation.ispartofCancer Cell International
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectmiR34a
dc.subjecttumorigenesis
dc.subjectnano-delivery systems
dc.subjectcancer treatment
dc.subjectp53 signaling
dc.titleTargeted therapy using nanocomposite delivery systems in cancer treatment: highlighting miR34a regulation for clinical applications
dc.typeReview Article

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu